Induced pluripotent stem cell (iPSC) Platform

Pluripotent stem cells are cells that have the capacity to self-renew and to develop into the three primary germ cell layers of the early embryo and therefore into any cell type. Induced pluripotent stem cells or iPSCs are reprogrammed adult cells that have the same capacity. New data has shown that ReNeuron’s proprietary human neural stem cell line (CTX) can be readily reprogrammed to pluripotency while maintaining its conditional immortalisation technology. Allowing the rapid development of new allogeneic cell lines as cell-based therapeutics or for the production of exosomes with specific tissue targeting.

New cell lines can be efficiently created as cell therapy candidates targeting a broad range of diseases. A number of different cell lines are currently being developed. As a result, there is a potential to expand our therapeutic portfolio by developing further therapeutic candidates for subsequent out-licensing. Our iPSCs research platform provides further scope for a wide range of industry partnerships. We also continue to develop strong relationships with academic leaders in all areas of cell therapy to understand where the technology will have the greatest impact.

There is also future potential to produce exosomes with the ability to target specific tissues within the body. The maintenance of the immortalisation technology within the new exosome producer cell lines will allow for the scaled production of highly consistent exosomes at a scale relevant for clinical development.